Ann: PAT-DX1 Clinical Target Indications Confirmed, page-149

the issue IMO is that there is still a waiting period that accumulators are taking advantage of

"PAT-DX1, Patrys is now preparing that product for early-stage clinical work from late 2019."

LATE 2019 is a fair way off albeit we could get snippets on the way that can assist our sp to take a northerly path

It seems that Patrys has positioned itself very well with the DX1 asset, and what was
originally in-licensed as a discrete asset actually has the attributes of being an asset platform with multiple and varied applications. We expect that the rest of 2018 and much of 2019 will see a continued accrual of favourable data around both PAT-DX1 and PAT-DX1-NP.